EiRx says molecules kill breast cancer cells, reduce tumor size

By Lisa Kerner

Charlotte, N.C., Sept. 19 - EiRx Therapeutics plc said in preclinical studies, a lead series of molecules, including ERX3722, demonstrated selective killing of breast cancer cells over non-cancerous breast cells. The studies identified ERX3722 as having favorable drug-like properties, such as metabolic stability and serum binding.

In vivo efficacy studies in mice bearing a subcutaneous human breast cancer xenograft resulted in reduced tumor volume of 50% at the higher doses with no toxic or side effects.

"The efficacy and selectivity of the molecule is very encouraging, and supports our approach of targeted apoptosis therapy in the treatment of cancer to limit toxicity and side effects associated with standard chemotherapy," the managing director of subsidiary EiRx Therapeutics Ltd., Finbarr Murphy, said in a news release.

EiRx Therapeutics is a research-driven health care company based in Cork, Ireland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.